AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus
Background Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.678 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | Suppl 3 |
container_start_page | 678 |
container_title | Annals of the rheumatic diseases |
container_volume | 71 |
creator | Kvarnström, M. Dzikaite, V. Ottosson, L. Gunnarsson, I. Svenungsson, E. Wahren-Herlenius, M. |
description | Background Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific clinical manifestations and thus prognosis. Ro/SSA and LA/SSB autoantibodies are common in lupus, and have been described to correlate with a milder phenotype. Objectives In the present study we wanted to investigate correlations of levels and clinical implications of Ro/SSA and La/SSB autoantibodies including autoantibodies directed towards the functional RING and B-Box domains of the Ro52 protein. Methods Blood samples from SLE patients (n=232) were analyzed for immunological parameters including autoantibodies. All patients were concurrently examined by a rheumatologist and a nurse and information on clinical manifestations and disease activity indices collected. Results Ro52 autoantibody levels associated with more variables than the other analyzed antibodies. Significance was found for disease activity measured with the SLAM score (p=0.031), several variables involved in secondary Sjögren’s syndrome (sSS) and items for a diagnosis of sSS: (sSS p=0.0041; whole unstimulated salivary flow less than 1.5 ml/15 minutes p=0.027; salivary production measurement p=0.0076, a positive Schirmer’s test p=0.046; tear production p=0.019), sedimentation rate (p=0.0003), levels of immunoglobulins (p=0.0003), and an inverse correlation with levels of lymphocytes (p=0.003) and leukocytes (p=0.011). Antibodies to the RING domain of Ro52, which is the functionally active domain with E3 ligase activity, were highly significant for disease activity (p |
doi_str_mv | 10.1136/annrheumdis-2012-eular.693 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777972488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008655431</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1638-90db0600a3ba01da543d0b3bf0761e140d4ccc246a033f972433c186e633eff83</originalsourceid><addsrcrecordid>eNqVkMuO0zAUQC0EEmXgHyxYZ-Y6Tu2UXal4jDTDCGZgwca6cRzqktrFD5ju2LDlI_kSHIIQW1Z-6Bxb9xDymMEpY1ycoXNha_K-t7GqgdWVySOGU7Hid8iCNaIttwLukgUA8KpZCXmfPIhxV47QsnZBfqyfQaF_fvu-zsmjS7bzvTWRJk_T1tAhO52sdziOR4pl-8XQYN3Hqvd7tI76gb69WtZn19drijF6bTEZ-tWmLdWjdVbjOGs2HWnhkcbcRZMm8YDJGpfijI_5kONDcm_AMZpHf9YT8u7F85vNq-ri6uX5Zn1RdUzwtlpB35W5AHmHwHpcNryHjncDSMEMa6BvtNZ1IxA4H1aybjjXrBVGcG6GoeUn5Mn87iH4z9nEpHY-hzJlVExKORntRD2dKR18jMEM6hDsHsNRMVBTf_VPfzX1V7_7q1K0yNUs25jM7V8TwyclJJdL9fr9Rl02lzdvgH9QsvDLme_2u__55xd2jKIV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777972488</pqid></control><display><type>article</type><title>AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus</title><source>BMJ Journals - NESLi2</source><creator>Kvarnström, M. ; Dzikaite, V. ; Ottosson, L. ; Gunnarsson, I. ; Svenungsson, E. ; Wahren-Herlenius, M.</creator><creatorcontrib>Kvarnström, M. ; Dzikaite, V. ; Ottosson, L. ; Gunnarsson, I. ; Svenungsson, E. ; Wahren-Herlenius, M.</creatorcontrib><description>Background Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific clinical manifestations and thus prognosis. Ro/SSA and LA/SSB autoantibodies are common in lupus, and have been described to correlate with a milder phenotype. Objectives In the present study we wanted to investigate correlations of levels and clinical implications of Ro/SSA and La/SSB autoantibodies including autoantibodies directed towards the functional RING and B-Box domains of the Ro52 protein. Methods Blood samples from SLE patients (n=232) were analyzed for immunological parameters including autoantibodies. All patients were concurrently examined by a rheumatologist and a nurse and information on clinical manifestations and disease activity indices collected. Results Ro52 autoantibody levels associated with more variables than the other analyzed antibodies. Significance was found for disease activity measured with the SLAM score (p=0.031), several variables involved in secondary Sjögren’s syndrome (sSS) and items for a diagnosis of sSS: (sSS p=0.0041; whole unstimulated salivary flow less than 1.5 ml/15 minutes p=0.027; salivary production measurement p=0.0076, a positive Schirmer’s test p=0.046; tear production p=0.019), sedimentation rate (p=0.0003), levels of immunoglobulins (p=0.0003), and an inverse correlation with levels of lymphocytes (p=0.003) and leukocytes (p=0.011). Antibodies to the RING domain of Ro52, which is the functionally active domain with E3 ligase activity, were highly significant for disease activity (p<0.0001). Conclusions Autoantibodies against Ro52 and the functional RING domain are important in lupus patients and associate more than Ro60 and La antibodies with clinical and laboratory features of the disease. The impact on the SLAM disease activity score was especially noted. Disclosure of Interest None Declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2012-eular.693</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.678</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/Suppl_3/678.7.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/Suppl_3/678.7.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3187,23562,27915,27916,77361,77392</link.rule.ids></links><search><creatorcontrib>Kvarnström, M.</creatorcontrib><creatorcontrib>Dzikaite, V.</creatorcontrib><creatorcontrib>Ottosson, L.</creatorcontrib><creatorcontrib>Gunnarsson, I.</creatorcontrib><creatorcontrib>Svenungsson, E.</creatorcontrib><creatorcontrib>Wahren-Herlenius, M.</creatorcontrib><title>AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific clinical manifestations and thus prognosis. Ro/SSA and LA/SSB autoantibodies are common in lupus, and have been described to correlate with a milder phenotype. Objectives In the present study we wanted to investigate correlations of levels and clinical implications of Ro/SSA and La/SSB autoantibodies including autoantibodies directed towards the functional RING and B-Box domains of the Ro52 protein. Methods Blood samples from SLE patients (n=232) were analyzed for immunological parameters including autoantibodies. All patients were concurrently examined by a rheumatologist and a nurse and information on clinical manifestations and disease activity indices collected. Results Ro52 autoantibody levels associated with more variables than the other analyzed antibodies. Significance was found for disease activity measured with the SLAM score (p=0.031), several variables involved in secondary Sjögren’s syndrome (sSS) and items for a diagnosis of sSS: (sSS p=0.0041; whole unstimulated salivary flow less than 1.5 ml/15 minutes p=0.027; salivary production measurement p=0.0076, a positive Schirmer’s test p=0.046; tear production p=0.019), sedimentation rate (p=0.0003), levels of immunoglobulins (p=0.0003), and an inverse correlation with levels of lymphocytes (p=0.003) and leukocytes (p=0.011). Antibodies to the RING domain of Ro52, which is the functionally active domain with E3 ligase activity, were highly significant for disease activity (p<0.0001). Conclusions Autoantibodies against Ro52 and the functional RING domain are important in lupus patients and associate more than Ro60 and La antibodies with clinical and laboratory features of the disease. The impact on the SLAM disease activity score was especially noted. Disclosure of Interest None Declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqVkMuO0zAUQC0EEmXgHyxYZ-Y6Tu2UXal4jDTDCGZgwca6cRzqktrFD5ju2LDlI_kSHIIQW1Z-6Bxb9xDymMEpY1ycoXNha_K-t7GqgdWVySOGU7Hid8iCNaIttwLukgUA8KpZCXmfPIhxV47QsnZBfqyfQaF_fvu-zsmjS7bzvTWRJk_T1tAhO52sdziOR4pl-8XQYN3Hqvd7tI76gb69WtZn19drijF6bTEZ-tWmLdWjdVbjOGs2HWnhkcbcRZMm8YDJGpfijI_5kONDcm_AMZpHf9YT8u7F85vNq-ri6uX5Zn1RdUzwtlpB35W5AHmHwHpcNryHjncDSMEMa6BvtNZ1IxA4H1aybjjXrBVGcG6GoeUn5Mn87iH4z9nEpHY-hzJlVExKORntRD2dKR18jMEM6hDsHsNRMVBTf_VPfzX1V7_7q1K0yNUs25jM7V8TwyclJJdL9fr9Rl02lzdvgH9QsvDLme_2u__55xd2jKIV</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Kvarnström, M.</creator><creator>Dzikaite, V.</creator><creator>Ottosson, L.</creator><creator>Gunnarsson, I.</creator><creator>Svenungsson, E.</creator><creator>Wahren-Herlenius, M.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20130601</creationdate><title>AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus</title><author>Kvarnström, M. ; Dzikaite, V. ; Ottosson, L. ; Gunnarsson, I. ; Svenungsson, E. ; Wahren-Herlenius, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1638-90db0600a3ba01da543d0b3bf0761e140d4ccc246a033f972433c186e633eff83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kvarnström, M.</creatorcontrib><creatorcontrib>Dzikaite, V.</creatorcontrib><creatorcontrib>Ottosson, L.</creatorcontrib><creatorcontrib>Gunnarsson, I.</creatorcontrib><creatorcontrib>Svenungsson, E.</creatorcontrib><creatorcontrib>Wahren-Herlenius, M.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kvarnström, M.</au><au>Dzikaite, V.</au><au>Ottosson, L.</au><au>Gunnarsson, I.</au><au>Svenungsson, E.</au><au>Wahren-Herlenius, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>71</volume><issue>Suppl 3</issue><spage>678</spage><pages>678-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Systemic lupus erythematosus (SLE) is a disease with immunological dysregulation, and affects patients commonly carrying autoantibodies in combination with involvement of at least two organ systems affected by inflammation. The different autoantibody specificities correlate with specific clinical manifestations and thus prognosis. Ro/SSA and LA/SSB autoantibodies are common in lupus, and have been described to correlate with a milder phenotype. Objectives In the present study we wanted to investigate correlations of levels and clinical implications of Ro/SSA and La/SSB autoantibodies including autoantibodies directed towards the functional RING and B-Box domains of the Ro52 protein. Methods Blood samples from SLE patients (n=232) were analyzed for immunological parameters including autoantibodies. All patients were concurrently examined by a rheumatologist and a nurse and information on clinical manifestations and disease activity indices collected. Results Ro52 autoantibody levels associated with more variables than the other analyzed antibodies. Significance was found for disease activity measured with the SLAM score (p=0.031), several variables involved in secondary Sjögren’s syndrome (sSS) and items for a diagnosis of sSS: (sSS p=0.0041; whole unstimulated salivary flow less than 1.5 ml/15 minutes p=0.027; salivary production measurement p=0.0076, a positive Schirmer’s test p=0.046; tear production p=0.019), sedimentation rate (p=0.0003), levels of immunoglobulins (p=0.0003), and an inverse correlation with levels of lymphocytes (p=0.003) and leukocytes (p=0.011). Antibodies to the RING domain of Ro52, which is the functionally active domain with E3 ligase activity, were highly significant for disease activity (p<0.0001). Conclusions Autoantibodies against Ro52 and the functional RING domain are important in lupus patients and associate more than Ro60 and La antibodies with clinical and laboratory features of the disease. The impact on the SLAM disease activity score was especially noted. Disclosure of Interest None Declared</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2012-eular.693</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.678 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1777972488 |
source | BMJ Journals - NESLi2 |
title | AB0693 Autoantibodies to the functionally active ring-domain of RO52/SSA associate with clinical activity in a subset of patients with lupus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A50%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0693%E2%80%85Autoantibodies%20to%20the%20functionally%20active%20ring-domain%20of%20RO52/SSA%20associate%20with%20clinical%20activity%20in%20a%20subset%20of%20patients%20with%20lupus&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Kvarnstr%C3%B6m,%20M.&rft.date=2013-06-01&rft.volume=71&rft.issue=Suppl%203&rft.spage=678&rft.pages=678-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2012-eular.693&rft_dat=%3Cproquest_cross%3E4008655431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777972488&rft_id=info:pmid/&rfr_iscdi=true |